Literature DB >> 10226356

Study of the enzymatic degradation of vasostatin I and II and their precursor chromogranin A by dipeptidyl peptidase IV using high-performance liquid chromatography/electrospray mass spectrometry.

X Y Zhang1, I De Meester, A M Lambeir, L Dillen, W Van Dongen, E L Esmans, A Haemers, S Scharpé, M Claeys.   

Abstract

The interaction of dipeptidyl peptidase IV with structurally related proteins differing in chain length, namely vasostatin I and II and their precursor protein chromogranin A, was examined using high-performance liquid chromatography in combination with electrospray mass spectrometry. Suitable analytical procedures were developed involving the use of reversed-phase high-performance liquid chromatography for purification of the enzymatic degradation products and a peptide mapping procedure for evaluating the enzymatic degradation of the large precursor protein chromogranin A. While vasostatin I was found to be a substrate for dipeptidyl peptidase IV, no N-terminal cleavage of Leu-Pro could be noted for chromogranin A. With respect to vasostatin II, N-terminal degradation was only observed after degradation in the C-terminal domain to proteins containing < or = 78 amino acids. The specificity of the N-terminal release of Leu-Pro was proved by addition of a DPP IV specific inhibitor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10226356     DOI: 10.1002/(SICI)1096-9888(199904)34:4<255::AID-JMS752>3.0.CO;2-7

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  3 in total

1.  The N-terminal fragment of chromogranin A, vasostatin-1 protects mice from acute or chronic colitis upon oral administration.

Authors:  Cristiano Rumio; Giuseppina F Dusio; Barbara Colombo; Anna Gasparri; Diego Cardani; Fabrizio Marcucci; Angelo Corti
Journal:  Dig Dis Sci       Date:  2012-01-26       Impact factor: 3.199

Review 2.  Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance.

Authors:  Ashwani Sharma; Tarun Virmani; Anjali Sharma; Vaishnavi Chhabra; Girish Kumar; Kamla Pathak; Abdulsalam Alhalmi
Journal:  Diabetes Metab Syndr Obes       Date:  2022-06-16       Impact factor: 3.249

Review 3.  Dipeptidyl peptidase-4: a key player in chronic liver disease.

Authors:  Minoru Itou; Takumi Kawaguchi; Eitaro Taniguchi; Michio Sata
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.